ProfileGDS5678 / 1452971_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 79% 79% 82% 78% 81% 79% 80% 80% 79% 79% 79% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5413380
GSM967853U87-EV human glioblastoma xenograft - Control 25.5410979
GSM967854U87-EV human glioblastoma xenograft - Control 35.5380879
GSM967855U87-EV human glioblastoma xenograft - Control 46.0495682
GSM967856U87-EV human glioblastoma xenograft - Control 55.4738878
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5504981
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3318879
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.579580
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6030580
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5190279
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5254679
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5279979
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.539179
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5304279